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Zygomycosis are invasive mould infections, rarely diagnosed in hematologic patients. Most of the cases published are in patients
with prolonged neutropenia, along with other risk factors such as the use of prior broad-spectrum antibiotics (including new
antifungal agents, such as voriconazole), diabetes mellitus (with or without ketoacidosis), malnutrition, iron overload (with or
without the use of deferoxamine). These infections have poor prognosis due to the involvement of vital anatomic structures and
late diagnosis. Until recent years, the treatment was based on high doses of amphotericin B plus surgical debridement. Here we
present two patients with hematologic diseases (one with leukemia, the second with aplastic anemia) with an impaired immune
system and the diagnosis of zygomycosis. The survival of one of them was mainly due to early diagnosis and surgical debridement;
unfortunately the second was misdiagnosed as an extensive ecchymosis due to thrombocytopenia and died with CNS involvement.
1.Introduction
Most invasive fungal infections occur in patients with
hematologic malignancies, and the prevalence has increased
steadily in recent years. This phenomenon is attributed
to host defense impairment due to intensive cytotoxic
chemotherapies, stem cell transplantation, myeloablative ra-
diation therapy, and the use of corticosteroids, cyclosporine,
or new immunosuppressive agents. Although Candida is the
main fungal agent involved in invasive fungal infection (IFI),
an increasing number of infections are caused by molds,
mostly Aspergillus spp, but in the last 20 years other emerging
fungal pathogens such as Zygomycetes have appeared with
high mortality rates [1]. We present two similar cases with
diﬀerent evolutions.
2.ClinicalCases
Patient no. 1 wasa 55-year-old male, referredto our hospital,
with a 4-month history of fatigue, weight loss, anorexia,
nocturnal diaphoresis, occasional vertigo, and recent sev-
eral ecchymoses below both knees. On admission he was
found pale, with multiple vesicles on lips and cheeks,
and cervical lymphadenopathies (larger than 1cm). The
hemogram showed leukocytes 11.8/mm3, 10.6/mm3 lym-
phocytes (89%), 0.5/mm3 neutrophils (4%), hemoglobin
level 10.6g/dL, and 38/mm3 platelets. A blood smear was
performed, describing blasts somewhat large with a varied
morphology which was classiﬁed as Acute Lymphoblastic
Leukemia (ALL) L2 according to French-American-British
(FAB) classiﬁcation. An additional diagnosis of herpes
simplex virus infection was made. He was put on Cancer and
Leukemia Group B (CALBG) scheme and intravenous acy-
clovir and hospitalized. Two weeks later he developed fever
associated to profound neutropenia (100/mm3), and cef-
tazidimeplusamikacinwasaddedtothetreatmentaccording
to Infectious Diseases Society of America (IDSA) guidelines.
Four days later, due to persistent fever, vancomycin was
added with incomplete defervescence. All cultures were
negative,andnosourceofinfectionwasidentiﬁed.Onday142 Case Reports in Infectious Diseases
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Figure 1: (a) CT scan of patient with invasion of left paranasal sinuses and orbit. (b) Necrotic sinus tissue found on endoscopy.
Figure 2: Biopsy with silver stain showing large pauciseptate hy-
phae invading tissue.
Figure 3: Sporangiophores with big sporangia, with no apophysis,
rhizoids or stolones, compatible with Mucor sp.
ofchemotherapy,hecomplainedofperiorbitalpainathisleft
eye. He was found to have slight proptosis and conjunctival
hemorrhage. Because of persistent fever, and the sinus
maxillaryclinicalsigns,aCTscanoftheheadwasperformed;
it showed a solid image inside the left maxillary sinus,
proptosis of the left eyeball, and destruction of the structures
Figure 4: Aspect of patient with periorbital edema and ecchymosis
of the surrounding skin.
adjacenttothenose(Figure1(a)).Followingtheseﬁndings,a
nasal endoscopy was performed promptly, and it showed an
extensive necrosis of the left medial turbinate (Figure 1(b)).
Anincisionalbiopsyreportshowednecrosisandhemorrhage
with nonseptate hyphae 90◦ degree branched (Figure 2), and
Mucor sp. was identiﬁed on culture (Figure 3) since the
ﬁrst procedure intranasal amphotericin was instilled. During
a 4-week period, three nasal endoscopies were performed
until necrotic tissue disappeared, along with antibacterial
and antifungal therapies (amphotericin B 75mg daily).
AmphotericinBwasdiscontinuedaftercompleting1.0gram,
then switched to itraconazole. He was able to be continued
on the chemotherapy protocol and ultimately recovered
from neutropenia. He was kept on itraconazole during
the following chemotherapy administrations, until he was
declared free of disease. Until now, he is in remission of his
ALL.
Patient no. 2 was a 54-year-old female with uncontrolled
diabetes mellitus who was referred to our institution from
a regional hospital with a 4-month history of fatigue,
malaise, petechiae, and ecchymoses in the lower extremities.
Due to the initial presumptive diagnosis of idiopathic
thrombocytopenic purpura (ITP), she had been previouslyCase Reports in Infectious Diseases 3
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Figure 5: (a) KOH exam showing nonseptate hyphae branched at 90◦degrees. (b) Sporangiophores with sporangia and underdeveloped
stolones, compatible with Rhizomucor sp.
treated with prednisone 50mg/d and several blood packages
and platelet transfusions used. When a trend towards
pancytopenia was identiﬁed, she was referred with the
diagnosis of aplastic anemia. On arrival her vital signs
were unstable, she was found to have facial asymmetry,
periorbital edema, and bilateral proptosis (mainly right eye)
with ecchymosis of the surrounding skin, her right pupil
did not react to light stimuli (Figure 4). She had epistaxis
along with multiple large ecchymosis and petechiae all
over her body. Her laboratories showed 1.0/mm3 leucocytes
with 0.8/mm3 polymorphonuclear cells, hemoglobin level of
7gr/dL, platelet count 18.0/mm3; glucose 363mg/dL, serum
creatinine 1.51mg/dL, BUN 17.6g/dL, Na 140mEq/L, K
2.3mEq/L, albumin 2.6gr/dL, AL T 30UI/L, AST 49UI/L,
and bilirubin 2.88mg/dL. She was started on ceftazidime,
amikacin, and metronidazole with an insulin infusion and
potassium replenishment. A peripheral blood smear, which
was performed, showed some lymphocytes and neutrophils
and no platelets. A bone marrow aspirate revealed a hypocel-
lular bone marrow, with ﬁbrosis, no evidence of malignant
inﬁltration. A probable diagnosis of aplastic anemia under
recovery was made. The evolution was unfavourable; after an
urgent consultation to the Infectious Diseases Department
a CT scan revealed extensive areas of necrosis of her right
nostril, palate, and tongue. She was started on amphotericin
B 1.5mg/kg/d with a presumptive diagnosis of mucormyco-
sis suggesting a prompt surgical debridement, and a slide
smear and culture were taken. Unfortunately, before any
option could be initiated, she developed respiratory and
circulatory failure and died. Postmortem, a nasal biopsy and
swab were taken and found compatible with rhinocerebral
invasive zygomycosis due to the observation of nonseptate
hyphae branched at 90◦ degrees (Figure 5(a)). Two days later
a zygomycete was grown and identiﬁed as Rhizomucor spp.
(Figure 5(b)).
3. Discussion
Mucormycoses are uncommon but aggressive infections
caused by angiotropic fungi causing tissue necrosis, fre-
quently lethal in immunocompromised hosts. Mucor, Rhizo-
pus, Absidia, and Rhizomucor are the most common causal
a g e n t s .T h e s ef u n g ia r eu b i q u i t o u si nt h en a t u r ea n da r e
found in high organic matter and soil, but their potential
virulence in the human host is very low [2, 3]. They can
be acquired by inhalation, ingestion, or infecting wounds
[4]. They usually aﬀect the immunocompromised patient,
poorly controlled diabetic, iron overload states or treatment
with deferoxamine, and extensive burns [5]. The main
sites involved in cancer patients have been lungs, sinuses,
rhinocerebral, gastrointestinal tract, and soft tissue [2, 3, 6],
but rhinocerebral and pulmonary forms together with dis-
seminated disease have the highest mortality (78–100%) [5,
6]. Mucorales characteristically invade blood vessels, causing
thrombosis and infarction with necrosis and scarring. More
and more invasive fungal infections are being observed in
immunocompromisedpatientsoverthepast2decadeswhich
maybeexplainedbyanincreaseinthenumberofindividuals
with acquired immune deﬁcits and aggressive therapeutic
modalities like indwelling catheters, potent antineoplastic or
immunosuppressiveinterventions,andthewidespreaduseof
antimicrobial agents [7]. Recently it has been reported that
the use of voriconazole prophylaxis for invasive aspergillosis
in patients with hematologic neoplasias has increased the
incidence of infection by mucorales [8].
Sinusitis by mucorales should be suspected in patients
with fever of unknown origin, sinunasal symptoms, mucosal
discoloration, or anesthetic necrotic regions of the face or
oral cavity, any of these parts may contain necrotic areas
that allow prompt clues to the diagnosis when transoperative
studies are analyzed, including simple procedures such as4 Case Reports in Infectious Diseases
K OHtest(Figure5(a))[9].MucoralesentertheCNSthrough
adjacent structures, such as paranasal sinuses or eye orbit
where they can mimic a lymphoproliferative disorder. Com-
monly such patients complain of facial or orbital pain. At
physical examination some degree of proptosis, ophthalmo-
plegia, altered consciousness, and nasal discharge is evident.
Carotid artery thrombosis may occur [10].
Rapid diagnosis of mucormycosis is vital for manage-
ment and therapy since these infections progress rapidly.
Blood cultures are invariably negative (as in Aspergillosis),
and sputum cultures and bronchial washings are seldom
helpful. Fungal elements are easily detected in biopsies, nasal
scrapings, or sputum: wide, ribbon-like, nonseptate, hyaline
hyphae with KOH or Black Chlorazol. Special histopatho-
logical stains like Gomori-Grocott and Schiﬀ Peryodic Acid
Stain should be used. Mucorales grow in 2 or 3 days, and
genera are identiﬁed by morphologic characteristics of their
sporangia and sporangiophores. Only 30% of cultures are
positive [11].
Treatment should combine early aggressive surgical exci-
sion of the necrotic lesions, restoration of immune function
if possible, and amphotericin B at a dose of 1–1.5mg/kg
[3, 12–14], until remission is achieved. Once the infection
has been controlled, a chronic suppressive course with
amphotericin B should be considered for as long as the
immunosuppression persists. Among the new antifungal
drugs, posaconazole supposedly has in vivo action against
Rhizopus species but other new triazolic derivates such as ra-
vuconazole and voriconazole are inactive against mucorales,
just as the echinocandins [15, 16].
The mortality rate among cancer patients with mucor-
mycosisishigher,incontrastwithpatientswithoutanunder-
lying malignant disease [3]. This paper showed both sides
of mucormycotic involvement in hematologic patients: the
ﬁrst patient, even with an unfavourable prognosis due to the
ALL high-risk factors, had prompt intervention (appropriate
antifungal agent plus continuous surgical debridement)
which radically changed the course of this infection; mean-
while,thesecondpatientunfortunatelysuﬀeredthecommon
pitfalls associated with a delayed diagnosis invariably pro-
gressing to fatal outcome.
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